Zevra Therapeutics, Inc. Files 8-K

TL;DR

Zevra Therapeutics (formerly KemPharm) filed an 8-K confirming its name change.

AI Summary

Zevra Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting a name change from KemPharm, Inc. to Zevra Therapeutics, Inc. effective May 30, 2013. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Celebration, Florida.

Why It Matters

This filing confirms the official name change of the company, which is important for investors and stakeholders to identify the correct entity in financial markets and regulatory filings.

Risk Assessment

Risk Level: low — The filing is a routine administrative update confirming a past name change and does not introduce new financial or operational risks.

Key Numbers

• 001-36913 — SEC File Number (Identifies the company's filing with the SEC)
• 20-5894398 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Zevra Therapeutics, Inc. (company) — Registrant
• KemPharm, Inc. (company) — Former company name
• March 4, 2024 (date) — Filing date
• May 30, 2013 (date) — Date of name change
• Delaware (jurisdiction) — State of incorporation
• Celebration, FL (location) — Principal executive offices

FAQ

Filing Documents

• zvra20240303_8k.htm (8-K) — 33KB
• ex_633977.htm (EX-99.1) — 15KB
• picture3.jpg (GRAPHIC) — 6KB
• 0001437749-24-006365.txt ( ) — 189KB
• zvra-20240304.xsd (EX-101.SCH) — 3KB
• zvra-20240304_def.xml (EX-101.DEF) — 12KB
• zvra-20240304_lab.xml (EX-101.LAB) — 15KB
• zvra-20240304_pre.xml (EX-101.PRE) — 12KB
• zvra20240303_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 4, 2024, Zevra Therapeutics, Inc., a Delaware corporation, issued a press release announcing that the U.S. Food and Drug Administration, or FDA, extended the review period for the New Drug Application for arimoclomol, an investigational orally delivered, first-in-class treatment for Niemann-Pick disease type C. In addition, the FDA set a new Prescription Drug User Fee Act action date of September 21, 2024, and re-affirmed its intent to present the resubmission for discussion at an advisory committee meeting to be scheduled. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed: (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Zevra Therapeutics, Inc . Date: March 4, 2024 By: /s/ R. LaDuane Clifton R. LaDuane Clifton, MBA, CPA Chief Financial Officer, Secretary and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR